Literature DB >> 1346876

Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age.

R Booy1, S J Aitken, S Taylor, G Tudor-Williams, J A Macfarlane, E R Moxon, L A Ashworth, R T Mayon-White, H Griffiths, H M Chapel.   

Abstract

In the UK an accelerated schedule for immunisation against diphtheria, tetanus, and pertussis (injections at 2, 3, and 4 months of age) was introduced in 1990 to replace the more widely spaced schedule of 3, 5, and 9 months. There is concern, however, that the new schedule may be less immunogenic and therefore less protective than the old schedule. We have measured serum concentrations of antibodies against diphtheria, pertussis, and tetanus in infants immunised according to the two regimens. Both schedules resulted in protective concentrations of antibody against tetanus and diphtheria and in satisfactory antibody responses to three pertussis antigens (filamentous haemagglutinin, pertussis toxin, fimbriae). However, immunisation by the old schedule led to significantly higher antibody concentrations against both diphtheria and tetanus than did immunisation by the new schedule (p less than 0.01). In infants immunised with the new schedule, postimmunisation antibody concentrations against tetanus toxoid and against two pertussis antigens (pertussis toxin and fimbriae) were significantly lower in infants in whom preimmunisation (maternally derived) antibody concentrations were high (p less than 0.02). The findings suggest that with an accelerated immunisation schedule maternal antibodies can have an inhibitory effect on the responses to immunisation against tetanus and pertussis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346876     DOI: 10.1016/0140-6736(92)90336-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  30 in total

1.  A search for the evidence supporting community paediatric practice.

Authors:  M C Rudolf; N Lyth; A Bundle; G Rowland; A Kelly; S Bosson; M Garner; P Guest; M Khan; R Thazin; T Bennett; D Damman; V Cove; V Kaur
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

2.  NHS Reforms: The First Six Months--proof of progress or a statistical smokescreen? Radical Statistics Health Group.

Authors: 
Journal:  BMJ       Date:  1992-03-14

Review 3.  Immunisation of premature infants.

Authors:  J Bonhoeffer; C-A Siegrist; P T Heath
Journal:  Arch Dis Child       Date:  2006-11       Impact factor: 3.791

4.  Safety and effectiveness of an acellular pertussis vaccine in subjects with Down's syndrome.

Authors:  S Li Volti; T Mattina; L Mauro; S Bianca; S Anfuso; A Ursino; F Mollica
Journal:  Childs Nerv Syst       Date:  1996-02       Impact factor: 1.475

5.  Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Viet Nam.

Authors:  H A Hong; N T Ke; T N Nhon; N D Thinh; J W van der Gun; J T Hendriks; J G Kreeftenberg
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

Review 6.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

7.  Application of pulsed field gel electrophoresis to the 1993 epidemic of whooping cough in the UK.

Authors:  S N Syedabubakar; R C Matthews; N W Preston; D Owen; V Hillier
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

8.  Effect of beta propiolactone on specific antibody measurements by ELISA.

Authors:  A E Agbarakwe; S A Misbah; H Griffiths; H M Chapel
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

Review 9.  Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination.

Authors:  David R Martinez; Sallie R Permar; Genevieve G Fouda
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

10.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.